These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CALIFORNIA
|
94-2424084
|
|
(State
or other jurisdiction of
|
(IRS
Employer Identification Number)
|
|
incorporation or
organization)
|
|
|
|
|
|
400
KATO TERRACE, FREMONT, CA
|
94539
|
|
(Address of
principal executive offices)
|
(Zip
Code)
|
|
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
|
|
|
|
Non-accelerated
filer [ ]
|
Smaller
reporting company [X]
|
|
(Do not
check if a smaller reporting company)
|
|
|
|
|
|
Emerging growth
company [ ]
|
|
|
Item
1. Business
|
4
|
|
Item
1A. Risk Factors
|
9
|
|
Item
1B. Unresolved Staff Comments
|
15
|
|
Item 2.
Properties
|
15
|
|
Item
3. Legal Proceedings
|
15
|
|
Item
4. Mine Safety Disclosures
|
15
|
|
|
|
|
|
|
|
PART II
|
|
|
|
|
|
Item
5. Market for Registrant’s Common Equity,
Related Stockholder Matters and Issuer
Purchases of Equity
Securities
|
16
|
|
Item
6. Selected Consolidated Financial
Data
|
17
|
|
Item
7. Management’s Discussion and Analysis of
Financial Condition and Results of Operations
|
19
|
|
Item
7A. Quantitative and Qualitative Disclosures about Market
Risk
|
24
|
|
Item
8. Financial Statements and Supplementary
Data
|
26
|
|
Item
9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure
|
51
|
|
Item
9A. Controls and Procedures
|
51
|
|
Item
9B. Other Information
|
51
|
|
|
|
|
|
|
|
PART III
|
|
|
|
|
|
Item
10. Directors, Executive Officers and Corporate
Governance
|
52
|
|
Item
11. Executive Compensation
|
52
|
|
Item
12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder
Matters
|
52
|
|
Item
13. Certain Relationships and Related Transactions
|
52
|
|
Item
14. Principal Accountant Fees and Services
|
52
|
|
|
|
|
|
|
|
PART IV
|
|
|
|
|
|
Item
15. Exhibits, Financial Statement Schedules
|
53
|
|
|
|
|
|
|
|
Signatures
|
57
|
|
|
High
|
Low
|
|
Fiscal
2017:
|
|
|
|
First quarter ended August 31,
2016
|
$
3.42
|
$
0.96
|
|
Second quarter ended November 30,
2016
|
3.58
|
2.05
|
|
Third quarter ended February 28,
2017
|
5.28
|
2.15
|
|
Fourth quarter ended May 31,
2017
|
6.10
|
3.37
|
|
|
|
|
|
Fiscal
2016:
|
|
|
|
First quarter ended August 31,
2015
|
$
2.49
|
$
1.95
|
|
Second quarter ended November 30,
2015
|
2.50
|
1.72
|
|
Third quarter ended February 29,
2016
|
2.02
|
1.01
|
|
Fourth quarter ended May 31,
2016
|
1.76
|
0.95
|
|
|
Fiscal Year Ended May 31,
|
||||
|
|
2017
|
2016
|
2015
|
2014
|
2013
|
|
|
(In thousands, except per share
data)
|
||||
|
CONSOLIDATED
STATEMENTS OF OPERATIONS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
sales
|
$
18,898
|
$
14,501
|
$
10,018
|
$
19,684
|
$
16,488
|
|
Cost of sales
|
12,118
|
9,356
|
6,180
|
9,462
|
9,712
|
|
Gross profit
|
6,780
|
5,145
|
3,838
|
10,222
|
6,776
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
Selling, general and
administrative
|
7,052
|
6,975
|
6,470
|
6,323
|
6,872
|
|
Research
and development
|
4,657
|
4,324
|
4,062
|
3,402
|
3,211
|
|
|
|
|
|
|
|
|
Total operating
expenses
|
11,709
|
11,299
|
10,532
|
9,725
|
10,083
|
|
|
|
|
|
|
|
|
(Loss) income from operations
|
(4,929
)
|
(6,154
)
|
(6,694
)
|
497
|
(3,307
)
|
|
|
|
|
|
|
|
|
Interest expense
|
(678
)
|
(605
)
|
(130
)
|
(26
)
|
(49
)
|
|
Other (expense) income, net
|
(21
)
|
(16
)
|
211
|
(64
)
|
(33
)
|
|
|
|
|
|
|
|
|
(Loss)
income before income tax (expense)
benefit
|
(5,628
)
|
(6,775
)
|
(6,613
)
|
407
|
(3,389
)
|
|
|
|
|
|
|
|
|
Income tax (expense) benefit
|
(25
)
|
(10
)
|
(34
)
|
15
|
(30
)
|
|
Net (loss) income
|
(5,653
)
|
(6,785
)
|
(6,647
)
|
422
|
(3,419
)
|
|
Less:
Net income attributable to the noncontrolling
interest
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
|
|
Net
(loss) income attributable to Aehr
Test Systems common
shareholders
|
$
(5,653
)
|
$
(6,785
)
|
$
(6,647
)
|
$
422
|
$
(3,419
)
|
|
Net
(loss) income per share:
|
|
|
|
|
|
|
Basic
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
$
0.04
|
$
(0.36
)
|
|
Diluted
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
$
0.04
|
$
(0.36
)
|
|
|
|
|
|
|
|
|
Shares
used in per share calculations
|
|
|
|
|
|
|
Basic
|
16,267
|
13,091
|
12,047
|
10,877
|
9,549
|
|
Diluted
|
16,267
|
13,091
|
12,047
|
11,889
|
9,549
|
|
|
|
|
|
|
|
|
|
May 31,
|
||||
|
|
2017
|
2016
|
2015
|
2014
|
2013
|
|
CONSOLIDATED
BALANCE SHEETS:
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
17,803
|
$
939
|
$
5,527
|
$
1,809
|
$
2,324
|
|
Working capital
|
21,494
|
4,068
|
7,776
|
6,556
|
4,900
|
|
Total assets
|
30,892
|
10,046
|
14,868
|
12,225
|
10,975
|
|
|
|
|
|
|
|
|
Long-term obligations, less current portion
|
6,214
|
6,089
|
3,799
|
79
|
280
|
|
Total shareholders' equity
(deficit)
|
16,794
|
(723
)
|
4,550
|
7,029
|
4,994
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
|
|
|
|
|
Net sales
|
100.0
%
|
100.0
%
|
100.0
%
|
|
Cost of sales
|
64.1
|
64.5
|
61.7
|
|
Gross profit
|
35.9
|
35.5
|
38.3
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
Selling, general and
administrative
|
37.3
|
48.1
|
64.6
|
|
Research and
development
|
24.7
|
29.8
|
40.5
|
|
|
|
|
|
|
Total operating
expenses
|
62.0
|
77.9
|
105.1
|
|
|
|
|
|
|
Loss from operations
|
(26.1
)
|
(42.4
)
|
(66.8
)
|
|
|
|
|
|
|
Interest expense
|
(3.6
)
|
(4.2
)
|
(1.3
)
|
|
Other (expense) income, net
|
(0.1
)
|
(0.1
)
|
2.1
|
|
|
|
|
|
|
Loss before income tax expense
|
(29.8
)
|
(46.7
)
|
(66.0
)
|
|
|
|
|
|
|
Income tax expense
|
(0.1
)
|
(0.1
)
|
(0.4
)
|
|
|
|
|
|
|
Net loss
|
(29.9
)
|
(46.8
)
|
(66.4
)
|
|
Less:
Net income attributable to the noncontrolling
interest
|
--
|
--
|
--
|
|
Net
loss attributable to Aehr Test Systems
common shareholders
|
(29.9
)%
|
(46.8
)%
|
(66.4
)%
|
|
|
Payments Due by Period (in thousands)
|
||||
|
|
Total
|
Less than
1 year
|
1-3
years
|
3-5
years
|
5
years
|
|
Operating Leases
|
$
567
|
$
502
|
$
65
|
$
--
|
$
--
|
|
Convertible Notes
|
6,110
|
--
|
6,110
|
--
|
--
|
|
Interest on Convertible Notes
(1)
|
1,160
|
550
|
610
|
--
|
--
|
|
Purchases (2)
|
5,684
|
5,684
|
--
|
--
|
--
|
|
Total
|
$
13,521
|
$
6,736
|
$
6,785
|
$
--
|
$
--
|
|
Consolidated
Financial Statements of Aehr Test Systems
|
|
|
|
|
|
Report
of Independent Registered Public Accounting Firm
|
27
|
|
|
|
|
Consolidated
Balance Sheets at May 31, 2017 and 2016
|
28
|
|
|
|
|
Consolidated
Statements of Operations for the years ended May 31, 2017, 2016 and
2015
|
29
|
|
|
|
|
Consolidated
Statements of Comprehensive Loss for the years ended May 31, 2017,
2016 and 2015
|
30
|
|
|
|
|
Consolidated
Statements of Shareholders' Equity (Deficit) for the years ended
May 31, 2017, 2016 and 2015
|
31
|
|
|
|
|
Consolidated
Statements of Cash Flows for the years ended May 31, 2017, 2016 and
2015
|
32
|
|
|
|
|
Notes
to Consolidated Financial Statements
|
33
|
|
|
May 31,
|
|
|
|
2017
|
2016
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
17,803
|
$
939
|
|
Accounts receivable,
net
|
4,010
|
522
|
|
Inventories
|
6,604
|
7,033
|
|
Prepaid expenses and
other
|
961
|
254
|
|
|
|
|
|
Total current
assets
|
29,378
|
8,748
|
|
|
|
|
|
Property and equipment, net
|
1,419
|
1,204
|
|
Other assets
|
95
|
94
|
|
|
|
|
|
Total
assets
|
$
30,892
|
$
10,046
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS' EQUITY (DEFICIT)
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts payable
|
$
2,808
|
$
1,413
|
|
Accrued
expenses
|
1,609
|
1,553
|
|
Customer deposits and deferred
revenue
|
3,467
|
1,714
|
|
|
|
|
|
Total current
liabilities
|
7,884
|
4,680
|
|
|
|
|
|
Convertible notes, net of debt issuance
costs
|
6,110
|
5,962
|
|
Deferred revenue, long-term
|
104
|
127
|
|
|
|
|
|
Total
liabilities
|
14,098
|
10,769
|
|
|
|
|
|
Commitments
and contingencies (Note 16)
|
|
|
|
|
|
|
|
Aehr
Test Systems shareholders' equity (deficit):
|
|
|
|
Preferred stock, $0.01 par value:
Authorized: 10,000
shares;
Issued and outstanding: none
|
--
|
--
|
|
Common
stock, $0.01 par value:
Authorized: 75,000 shares;
Issued and outstanding: 21,340 shares and 13,216
shares at
May 31, 2017 and 2016, respectively
|
213
|
132
|
|
Additional paid-in capital
|
81,128
|
58,052
|
|
Accumulated other comprehensive
income
|
2,249
|
2,237
|
|
Accumulated deficit
|
(66,777
)
|
(61,124
)
|
|
Total Aehr Test Systems
shareholders' equity (deficit)
|
16,813
|
(703
)
|
|
Noncontrolling interest
|
(19
)
|
(20
)
|
|
Total shareholders'
equity (deficit)
|
16,794
|
(723
)
|
|
|
|
|
|
Total liabilities
and shareholders' equity (deficit)
|
$
30,892
|
$
10,046
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
|
|
|
|
|
Net sales
|
$
18,898
|
$
14,501
|
$
10,018
|
|
Cost of sales
|
12,118
|
9,356
|
6,180
|
|
Gross profit
|
6,780
|
5,145
|
3,838
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
Selling, general and
administrative
|
7,052
|
6,975
|
6,470
|
|
Research and
development
|
4,657
|
4,324
|
4,062
|
|
|
|
|
|
|
Total operating
expenses
|
11,709
|
11,299
|
10,532
|
|
|
|
|
|
|
Loss from operations
|
(4,929
)
|
(6,154
)
|
(6,694
)
|
|
|
|
|
|
|
Interest expense
|
(678
)
|
(605
)
|
(130
)
|
|
Other (expense) income, net
|
(21
)
|
(16
)
|
211
|
|
|
|
|
|
|
Loss before income tax expense
|
(5,628
)
|
(6,775
)
|
(6,613
)
|
|
|
|
|
|
|
Income tax expense
|
(25
)
|
(10
)
|
(34
)
|
|
Net loss
|
(5,653
)
|
(6,785
)
|
(6,647
)
|
|
Less:
Net income attributable
to the noncontrolling interest
|
--
|
--
|
--
|
|
|
|
|
|
|
Net
loss attributable to Aehr Test Systems
common shareholders
|
$
(5,653
)
|
$
(6,785
)
|
$
(6,647
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share – basic and
diluted
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
|
Shares used in per share calculation –
basic
|
16,267
|
13,091
|
12,047
|
|
Shares used in per share calculation –
diluted
|
16,267
|
13,091
|
12,047
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
$
(5,653
)
|
$
(6,785
)
|
$
(6,647
)
|
|
|
|
|
|
|
Other comprehensive
income (loss), net of tax:
Foreign currency
translation income loss
|
13
|
4
|
(254
)
|
|
|
|
|
|
|
Total comprehensive
loss
|
(5,640
)
|
(6,781
)
|
(6,901
)
|
|
Less: Comprehensive
income (loss) attributable to
noncontrolling
interest
|
1
|
(2
)
|
3
|
|
|
|
|
|
|
Comprehensive
loss
, attributable to
Aehr Test Systems
|
$
(5,641
)
|
$
(6,779
)
|
$
(6,904
)
|
|
|
Common
Stock
|
Additional Paid-in
|
Accumulated Other Comprehensive
|
Accumulated
|
Total Aehr
Test Systems Shareholders' Equity |
Noncontrolling
|
Total Shareholders'
|
|
|
|
Shares
|
Amount
|
Capital
|
Income
|
Deficit
|
(Deficit)
|
Interest
|
Equity
(Deficit)
|
|
Balances,
May 31, 2014
|
11,203
|
$
112
|
$
52,142
|
$
2,488
|
$
(47,692
)
|
$
7,050
|
$
(21
)
|
$
7,029
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock
under private
placement
|
1,065
|
11
|
2,563
|
--
|
--
|
2,574
|
--
|
2,574
|
|
Issuance of common stock
under employee plans
|
589
|
6
|
849
|
--
|
--
|
855
|
--
|
855
|
|
Stock-based
compensation
|
--
|
--
|
993
|
--
|
--
|
993
|
--
|
993
|
|
Net
loss
|
--
|
--
|
--
|
--
|
(6,647
)
|
(6,647
)
|
--
|
(6,647
)
|
|
Foreign currency
translation adjustment
|
--
|
--
|
--
|
(257
)
|
--
|
(257
)
|
3
|
(254
)
|
|
|
|
|
|
|
|
|
|
|
|
Balances,
May 31, 2015
|
12,857
|
129
|
56,547
|
2,231
|
(54,339
)
|
4,568
|
(18
)
|
4,550
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock
under employee plans
|
359
|
3
|
509
|
--
|
--
|
512
|
--
|
512
|
|
Stock-based
compensation
|
--
|
--
|
996
|
--
|
--
|
996
|
--
|
996
|
|
Net
loss
|
--
|
--
|
--
|
--
|
(6,785
)
|
(6,785
)
|
--
|
(6,785
)
|
|
Foreign currency
translation adjustment
|
--
|
--
|
--
|
6
|
--
|
6
|
(2
)
|
4
|
|
|
|
|
|
|
|
|
|
|
|
Balances,
May 31, 2016
|
13,216
|
132
|
58,052
|
2,237
|
(61,124
)
|
(703
)
|
(20
)
|
(723
)
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock
under employee plans
|
779
|
8
|
696
|
--
|
--
|
704
|
--
|
704
|
|
Issuance of common stock
under public offering
|
4,423
|
44
|
15,788
|
--
|
--
|
15,832
|
--
|
15,832
|
|
Issuance of common stock
under private
offering
|
2,722
|
27
|
5,272
|
--
|
--
|
5,299
|
--
|
5,299
|
|
Issuance of common stock in
consideration for
cancellation
of outstanding vendor
invoice
|
200
|
2
|
321
|
--
|
--
|
323
|
--
|
323
|
|
Stock-based compensation
|
--
|
--
|
999
|
--
|
--
|
999
|
--
|
999
|
|
Net
loss
|
--
|
--
|
--
|
--
|
(5,653
)
|
(5,653
)
|
--
|
(5,653
)
|
|
Foreign currency
translation adjustment
|
--
|
--
|
--
|
12
|
--
|
12
|
1
|
13
|
|
|
|
|
|
|
|
|
|
|
|
Balances,
May 31, 2017
|
21,340
|
$
213
|
$
81,128
|
$
2,249
|
$
(66,777
)
|
$
16,813
|
$
(19
)
|
$
16,794
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Cash
flows from operating activities:
|
|
|
|
|
Net loss
|
$
(5,653
)
|
$
(6,785
)
|
$
(6,647
)
|
|
Adjustments to reconcile net loss to net cash used in
operating activities:
|
|
|
|
|
Stock-based compensation
expense
|
999
|
1,016
|
997
|
|
Provision (recovery of)
for doubtful accounts
|
53
|
(13
)
|
(30
)
|
|
Loss on disposal of
asset
|
--
|
2
|
--
|
|
Amortization of debt
issuance cost
|
148
|
177
|
31
|
|
Depreciation and
amortization
|
271
|
203
|
135
|
|
Changes
in operating assets and liabilities:
|
|
|
|
|
Accounts
receivable
|
(3,507
)
|
887
|
1,774
|
|
Inventories
|
430
|
70
|
(1,008
)
|
|
Prepaid
expenses and other
|
(707
)
|
9
|
34
|
|
Accounts
payable
|
1,686
|
564
|
(850
)
|
|
Accrued
expenses
|
53
|
539
|
(371
)
|
|
Customer
deposits and deferred revenue
|
1,730
|
(2,909
)
|
3,702
|
|
Income taxes
payable
|
2
|
(41
)
|
(15
)
|
|
Deferred
rent
|
--
|
--
|
(8
)
|
|
Net
cash used in operating activities
|
(4,495
)
|
(6,281
)
|
(2,256
)
|
|
|
|
|
|
|
Cash
flows from investing activities:
|
|
|
|
|
Purchases of property and
equipment
|
(477
)
|
(919
)
|
(118
)
|
|
Net
cash used in investing activities
|
(477
)
|
(919
)
|
(118
)
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
Line of credit borrowings
(repayments), net
|
--
|
2,000
|
(777
)
|
|
Proceeds from issuance of
convertible notes, net
|
--
|
(6
)
|
3,760
|
|
Proceeds from issuance of common stock
under public
offering, net of issuance costs
|
15,832
|
--
|
--
|
|
Proceeds from issuance of common stock
under private
placement, net of issuance costs
|
5,299
|
--
|
2,574
|
|
Proceeds from issuance of common stock
under employee
plans
|
704
|
512
|
855
|
|
Net
cash provided by financing activities
|
21,835
|
2,506
|
6,412
|
|
|
|
|
|
|
|
|
|
|
|
Effect
of exchange rates on cash and
cash equivalents
|
1
|
106
|
(320
)
|
|
|
|
|
|
|
Net increase (decrease) in cash and
cash equivalents
|
16,864
|
(4,588
)
|
3,718
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of
year
|
939
|
5,527
|
1,809
|
|
Cash and cash equivalents, end of
year
|
$
17,803
|
$
939
|
$
5,527
|
|
|
|
|
|
|
Supplemental
cash flow information:
|
|
|
|
|
Cash
paid during the year for:
|
|
|
|
|
Income
taxes
|
$
18
|
$
47
|
$
26
|
|
Interest
|
$
516
|
$
302
|
$
130
|
|
|
|
|
|
|
Supplemental
disclosure of non-cash flow information:
|
|
|
|
|
Net
change in capitalized stock-based compensation
|
$
--
|
$
(20
)
|
$
(4
)
|
|
Line
of credit converted to convertible notes
|
$
--
|
$
2,000
|
$
--
|
|
Fair
value of common stock issued to settle accounts
payable
|
$
323
|
$
--
|
$
--
|
|
|
Balance as of
|
|
|
|
|
|
May 31, 2017
|
Level 1
|
Level 2
|
Level 3
|
|
Money market funds
|
$
15,516
|
$
15,516
|
$
--
|
$
--
|
|
Certificate of deposit
|
50
|
--
|
50
|
--
|
|
Assets
|
$
15,566
|
$
15,516
|
$
50
|
$
--
|
|
|
|
|
|
|
|
|
Balance as of
|
|
|
|
|
|
May 31, 2016
|
Level 1
|
Level 2
|
Level 3
|
|
Money market funds
|
$
1
|
$
1
|
$
--
|
$
--
|
|
Certificate of deposit
|
50
|
--
|
50
|
--
|
|
Assets
|
$
51
|
$
1
|
$
50
|
$
--
|
|
|
|
|
|
|
|
Furniture
and fixtures
|
2 to 6
years
|
|
Machinery
and equipment
|
3 to 6
years
|
|
Test
equipmen
t
|
4 to 6
years
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Stock-based
compensation in the form of stock options,
RSUs, and ESPP
purchase rights, included in:
|
|
|
|
|
Cost of sales
|
$
91
|
$
87
|
$
70
|
|
Selling, general and
administrative
|
714
|
723
|
726
|
|
Research and development
|
194
|
206
|
201
|
|
Net effect on net loss
|
$
999
|
$
1,016
|
$
997
|
|
Effect
on net loss per share:
|
|
|
|
|
Basic
|
$
0.06
|
$
0.08
|
$
0.08
|
|
Diluted
|
$
0.06
|
$
0.08
|
$
0.08
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Option
plan shares
|
|
|
|
|
Expected term (in years)
|
4
|
4
|
4
|
|
Volatility
|
0.81
|
0.86
|
0.90
|
|
Risk-free interest rates
|
1.02
%
|
1.21
%
|
1.20
%
|
|
Weighted-average grant date fair
value
|
$
1.09
|
$
1.31
|
$
1.52
|
|
|
Year End May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Employee
stock purchase plan shares
|
|
|
|
|
Expected term (in years)
|
0.5 – 2.0
|
0.5 – 2.0
|
0.5 – 2.0
|
|
Volatility
|
0.79 – 1.08
|
0.64 – 0.74
|
0.55 – 0.83
|
|
Risk-free interest rates
|
0.48%–0.80%
|
0.40%–0.76%
|
0.04%–0.55%
|
|
Weighted-average grant date fair
value
|
$
1.65
|
$
0.80
|
$
1.43
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Numerator: Net loss
|
$
(5,653
)
|
$
(6,785
)
|
$
(6,647
)
|
|
|
|
|
|
|
Denominator
for basic net loss per share:
|
|
|
|
|
Weighted-average shares
outstanding
|
16,267
|
13,091
|
12,047
|
|
|
|
|
|
|
Shares used in basic net loss per share
calculation
|
16,267
|
13,091
|
12,047
|
|
|
|
|
|
|
Effect of dilutive securities
|
--
|
--
|
--
|
|
|
|
|
|
|
Denominator for diluted net loss per
share
|
16,267
|
13,091
|
12,047
|
|
|
|
|
|
|
Basic net loss per share
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
|
|
|
|
|
|
Diluted net loss per share
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
|
|
May 31,
|
|
|
|
2017
|
2016
|
|
Accounts receivable
|
$
4,071
|
$
530
|
|
Less: Allowance for doubtful accounts
|
(61
)
|
(8
)
|
|
|
$
4,010
|
$
522
|
|
|
|
Additions
|
|
|
|
|
Balance at
|
charged to
|
|
Balance
|
|
|
beginning
|
costs and
|
|
at end
|
|
|
of year
|
expenses
|
Deductions*
|
of year
|
|
|
|
|
|
|
|
Allowance
for doubtful
accounts receivable:
|
|
|
|
|
|
May
31, 2017
|
$
8
|
$
53
|
$
--
|
$
61
|
|
|
|
|
|
|
|
May
31, 2016
|
$
21
|
$
--
|
$
(13
)
|
$
8
|
|
|
May 31,
|
|
|
|
2017
|
2016
|
|
Raw materials and
sub-assemblies
|
$
4,268
|
$
2,839
|
|
Work in process
|
2,059
|
4,151
|
|
Finished goods
|
277
|
43
|
|
|
$
6,604
|
$
7,033
|
|
|
May 31,
|
|
|
|
2017
|
2016
|
|
Leasehold improvements
|
$
1,145
|
$
1,072
|
|
Furniture and fixtures
|
974
|
974
|
|
Machinery and equipment
|
3,035
|
2,330
|
|
Test equipment
|
2,268
|
2,581
|
|
|
|
|
|
|
7,422
|
6,957
|
|
Less:
Accumulated depreciation
and
amortization
|
(6,003
)
|
(5,753
)
|
|
|
$
1,419
|
$
1,204
|
|
|
May 31,
|
|
|
|
2017
|
2016
|
|
|
|
|
|
Balance at the beginning of the
year
|
$
155
|
$
137
|
|
Accruals for warranties issued during the
year
|
123
|
334
|
|
Accruals
and adjustments (change in estimates) related
to
pre-existing warranties during the year
|
(54
)
|
--
|
|
Settlement made during the year (in cash or in
kind)
|
(111
)
|
(316
)
|
|
|
|
|
|
Balance at the end of the year
|
$
113
|
$
155
|
|
|
May
31,
|
|
|
|
2017
|
2016
|
|
Payroll related
|
$
934
|
$
706
|
|
Professional services
|
161
|
166
|
|
Accrued interest
|
139
|
110
|
|
Commissions and bonuses
|
125
|
227
|
|
Warranty
|
113
|
155
|
|
Taxes payable
|
69
|
63
|
|
Investor relations
|
25
|
88
|
|
Other
|
43
|
38
|
|
|
$
1,609
|
$
1,553
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Domestic
|
$
(5,663
)
|
$
(6,794
)
|
$
(6,871
)
|
|
Foreign
|
35
|
19
|
258
|
|
|
$
(5,628
)
|
$
(6,775
)
|
$
(6,613
)
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Federal
income taxes:
|
|
|
|
|
Current
|
$
--
|
$
--
|
$
--
|
|
Deferred
|
--
|
--
|
--
|
|
State
income taxes:
|
|
|
|
|
Current
|
(8
)
|
3
|
(19
)
|
|
Deferred
|
--
|
--
|
--
|
|
Foreign
income taxes:
|
|
|
|
|
Current
|
(17
)
|
(13
)
|
(15
)
|
|
Deferred
|
--
|
--
|
--
|
|
|
$
(25
)
|
$
(10
)
|
$
(34
)
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
U.S. federal statutory tax
rate
|
34.0
%
|
34.0
%
|
34.0
%
|
|
State taxes, net of federal tax
effect
|
(0.1
)
|
--
|
(0.2
)
|
|
Foreign rate differential
|
0.1
|
0.2
|
1.4
|
|
Stock-based compensation
|
(2.8
)
|
(3.8
)
|
(2.2
)
|
|
Research and development credit
|
3.1
|
2.1
|
1.1
|
|
Change in valuation allowance
|
(33.8
)
|
(32.5
)
|
(34.4
)
|
|
Other
|
(0.9
)
|
(0.2
)
|
(0.2
)
|
|
Effective tax rate
|
(0.4
)%
|
(0.2
)%
|
(0.5
)%
|
|
|
Year Ended May 31,
|
|
|
|
2017
|
2016
|
|
|
|
|
|
Net operating losses
|
$
18,719
|
$
16,643
|
|
Credit carryforwards
|
4,715
|
4,430
|
|
Inventory reserves
|
870
|
1,064
|
|
Reserves and accruals
|
1,566
|
1,606
|
|
Other
|
393
|
885
|
|
|
|
|
|
|
26,263
|
24,628
|
|
|
|
|
|
Less: Valuation allowance
.
|
(26,263
)
|
(24,628
)
|
|
Net deferred tax assets
|
$
--
|
$
--
|
|
Beginning balance as of May 31,
2014
|
$
973
|
|
Decreases related to prior year tax
positions
|
--
|
|
Decreases related to lapse of statute of
limitations
|
(54
)
|
|
|
|
|
Balance at May 31, 2015
|
$
919
|
|
|
|
|
Decreases related to prior year tax
positions
|
(124
)
|
|
Decreases related to lapse of statute of
limitations
|
(6
)
|
|
|
|
|
Balance at May 31, 2016
|
$
789
|
|
|
|
|
Decreases related to prior year tax
positions
|
--
|
|
Decreases related to lapse of statute of
limitations
|
--
|
|
|
|
|
Balance at May 31, 2017
|
$
789
|
|
|
May 31,
|
|
|
|
2017
|
2016
|
|
Customer deposits
|
$
3,264
|
$
540
|
|
Deferred revenue
|
203
|
1,174
|
|
|
$
3,467
|
$
1,714
|
|
|
May 31,
|
May 31,
|
|
|
2017
|
2016
|
|
Principal
|
$
6,110
|
$
6,110
|
|
Unamortized debt issuance
costs
|
--
|
(148
)
|
|
|
$
6,110
|
$
5,962
|
|
|
Available
|
|
|
Shares
|
|
Balances, May 31, 2014
|
1,145
|
|
|
|
|
Additional shares reserved
|
860
|
|
Options granted
|
(1,253
)
|
|
Options terminated
|
93
|
|
|
|
|
Balances, May 31, 2015
|
845
|
|
|
|
|
Additional shares reserved
|
800
|
|
Options granted
|
(92
)
|
|
RSUs granted
|
(35
)
|
|
Options terminated
|
329
|
|
|
|
|
Balances, May 31, 2016
|
1,847
|
|
|
|
|
Additional shares reserved
|
2,238
|
|
Options granted
|
(368
)
|
|
RSUs granted
|
(157
)
|
|
Options terminated
|
55
|
|
Plan shares expired
|
(1,446
)
|
|
|
|
|
Balances, May 31, 2017
|
2,169
|
|
|
Outstanding Options
|
||
|
|
|
Weighted
|
|
|
|
Number
|
Average
|
Aggregate
|
|
|
of
|
Exercise
|
Intrinsic
|
|
|
Shares
|
Price
|
Value
|
|
Balances, May 31, 2014
|
3,002
|
$
1.31
|
$
2,913
|
|
|
|
|
|
|
Options granted
|
1,253
|
$
2.38
|
|
|
Options terminated
|
(93
)
|
$
2.30
|
|
|
Options exercised
|
(476
)
|
$
1.33
|
|
|
|
|
|
|
|
Balances, May 31, 2015
|
3,686
|
$
1.66
|
$
2,946
|
|
|
|
|
|
|
Options granted
|
92
|
$
2.12
|
|
|
Options terminated
|
(329
)
|
$
1.93
|
|
|
Options exercised
|
(248
)
|
$
1.34
|
|
|
|
|
|
|
|
Balances, May 31, 2016
|
3,201
|
$
1.66
|
$
189
|
|
|
|
|
|
|
Options granted
|
368
|
$
1.83
|
|
|
Options terminated
|
(55
)
|
$
1.42
|
|
|
Options exercised
|
(440
)
|
$
1.35
|
|
|
|
|
|
|
|
Balances, May 31, 2017
|
3,074
|
$
1.73
|
$
8,763
|
|
|
|
|
|
|
Options exercisable and expected to be
exercisable at May
31, 2017
|
3,030
|
$
1.72
|
$
8,654
|
|
|
Options
Outstanding
|
Options
Exercisable
|
|||||
|
|
at May 31,
2017
|
at May 31,
2017
|
|||||
|
Range of
Exercise
Prices
|
Number
Outstanding Shares
|
Weighted Average
Remaining Contractual Life (Years)
|
Weighted Average
Exercise Price
|
Number
Exercisable Shares
|
Weighted Average
Remaining Contractual Life (Years)
|
Weighted Average
Exercise Price
|
Aggregate
Intrinsic Value
|
|
$
0.59-$0.97
|
514
|
1.77
|
$
0.66
|
514
|
1.77
|
$
0.66
|
|
|
$
1.09-$1.40
|
784
|
2.41
|
$
1.28
|
773
|
2.40
|
$
1.28
|
|
|
$
1.68-$2.06
|
542
|
5.12
|
$
1.77
|
287
|
4.26
|
$
1.85
|
|
|
$
2.10-$2.81
|
1,234
|
4.53
|
$
2.44
|
848
|
4.46
|
$
2.46
|
|
|
|
|
|
|
|
|
|
|
|
$
0.59-$2.81
|
3,074
|
3.63
|
$
1.73
|
2,422
|
3.21
|
$
1.63
|
$7,148
|
|
|
Year Ended May 31,
|
||
|
|
2017
|
2016
|
2015
|
|
Foreign exchange (loss) gain
|
$
(21
)
|
$
(19
)
|
$
194
|
|
Other, net
|
--
|
3
|
17
|
|
|
$
(21
)
|
$
(16
)
|
$
211
|
|
|
United
|
|
|
|
|
|
States
|
Asia
|
Europe
|
Total
|
|
2017:
|
|
|
|
|
|
Net sales
|
$
7,762
|
$
10,439
|
$
697
|
$
18,898
|
|
Property and equipment,
net
|
1,364
|
40
|
15
|
1,419
|
|
|
|
|
|
|
|
2016:
|
|
|
|
|
|
Net sales
|
$
2,957
|
$
10,228
|
$
1,316
|
$
14,501
|
|
Property and equipment,
net
|
1,151
|
39
|
14
|
1,204
|
|
|
|
|
|
|
|
2015:
|
|
|
|
|
|
Net sales
|
$
3,648
|
$
4,943
|
$
1,427
|
$
10,018
|
|
Property and equipment,
net
|
432
|
34
|
12
|
478
|
|
Years
Ending May 31,
|
|
|
2018
|
$
502
|
|
2019
|
64
|
|
2020
|
1
|
|
2021
|
--
|
|
2022
|
--
|
|
Thereafter
|
--
|
|
Total
|
$
567
|
|
|
|
|
|
Three Months Ended
|
|||
|
|
Aug. 31,
|
Nov. 30,
|
Feb. 28,
|
May 31,
|
|
|
2016
|
2016
|
2017
|
2017
|
|
Net sales
|
$
5,318
|
$
4,216
|
$
2,681
|
$
6,683
|
|
Gross profit
|
$
2,206
|
$
1,463
|
$
503
|
$
2,608
|
|
Net loss
|
$
(755
)
|
$
(1,452
)
|
$
(2,651
)
|
$
(795
)
|
|
Net loss per share basic and
diluted
|
$
(0.06
)
|
$
(0.09
)
|
$
(0.16
)
|
$
(0.04
)
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|||
|
|
Aug. 31,
|
Nov. 30,
|
Feb. 29,
|
May 31,
|
|
|
2015
|
2015
|
2016
|
2016
|
|
Net sales
|
$
6,633
|
$
4,620
|
$
1,677
|
$
1,571
|
|
Gross profit
(loss)
|
$
3,383
|
$
1,691
|
$
169
|
$
(98
)
|
|
Net income (loss)
|
$
294
|
$
(1,048
)
|
$
(2,975
)
|
$
(3,056
)
|
|
Net income (loss) per share basic and
diluted
|
$
0.02
|
$
(0.08
)
|
$
(0.23
)
|
$
(0.23
)
|
|
|
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
3.1(1)
|
|
Restated
Articles of Incorporation of Registrant.
|
|
3.2(2)
|
|
Amended
and Restated Bylaws of Registrant.
|
|
4.1(3)
|
|
Form of
Common Stock certificate.
|
|
4.2(4)
|
|
Convertible
Note Purchase and Credit Facility Agreement, dated April 10, 2015,
by and among Aehr Test Systems, QVT Fund LP and Quintessence Fund
L.P.
|
|
4.3(5)
|
|
Amendment
to Convertible Note Purchase and Credit Facility Agreement and 9.0%
Notes, dated August 22, 2016, by and among Aehr Test Systems, QVT
Fund LP and Quintessence Fund L.P.
|
|
4.4
|
|
Form of
9.0% Convertible Secured Note due 2017 (included in Exhibit
4.2)
|
|
4.5
|
|
Form of
5.0% Secured Revolving Credit Note (included in Exhibit
4.2)
|
|
4.6(6)
|
|
Registration
Rights Agreement, dated April 10, 2015, by and among Aehr Test
Systems, QVT Fund LP and Quintessence Fund L.P.
|
|
4.7(7)
|
|
Registration
Rights Agreement by and among the Company and the Investors (as
defined therein), dated as of September 22, 2016.
|
|
10.1(8)
|
|
2006
Equity Incentive Plan.*
|
|
10.2(9)
|
|
Amended
and Restated 2006 Employee Stock Purchase Plan.*
|
|
10.3(10)
|
|
2016
Equity Incentive Plan.*
|
|
10.4(11)
|
|
Form of
Indemnification Agreement entered into between Registrant and its
directors and executive officers.*
|
|
10.5(12)
|
|
Form of
Change of Control Agreement.*
|
|
10.6(13)
|
|
Lease
dated August 3, 1999 for facilities located at Building C, 400 Kato
Terrace, Fremont, California.
|
|
10.6.1(14)
|
|
First
Amendment dated May 06, 2008 for facilities located at400 Kato
Terrace, Fremont, California.
|
|
10.6.2(15)
|
|
Second
Amendment dated November 7, 2014 for facilities located at400 Kato
Terrace, Fremont, California.
|
|
10.10(16)
|
|
Offer
Letter dated January 3, 2012, between the Company and Gayn
Erickson.*
|
|
10.11(17)
|
|
Offer
Letter dated March 5, 2013, between the Company and Rhea
Posedel.*
|
|
10.12(18)
|
|
Change
of Control Severance Agreement dated January 3, 2012, between the
Company and Gayn Erickson.*
|
|
10.13(19)
|
|
Amended
and Restated Change of Control Severance Agreement dated March 5,
2013, between the Company and Rhea J. Posedel.*
|
|
10.14(20)
|
|
Common
Stock Purchase Agreement by and among the Company and the Investors
(as defined therein), dated as of March 15, 2013.
|
|
10.15(21)
|
|
Common
Stock Purchase Agreement by and among the Company and the Investors
(as defined therein), dated as of November 24, 2014.
|
|
10.16(22)
|
|
Security
Agreement, dated April 10, 2015, by and among Aehr Test Systems,
QVT Fund LP and Quintessence Fund L.P.
|
|
10.17(23)
|
|
Form of
2006 Equity Incentive Plan Stock Option Award
Agreement.*
|
|
10.18(24)
|
|
Form of
2006 Equity Incentive Plan Restricted Stock Unit
Award.*
|
|
|
Form of
2016 Equity Incentive Plan Stock Option Award
Agreement.*
|
|
|
|
Form of
2016 Equity Incentive Plan Restricted Stock Unit
Award.*
|
|
|
10.21(25)
|
|
Purchase
Agreement by and among the Company and the Investors (as defined
therein), dated as of September 22, 2016.
|
|
|
Subsidiaries
of the Company.
|
|
|
|
Consent
of BPM LLP - Independent Registered Public Accounting Firm (filed
herewith).
|
|
|
24.1
|
|
Power
of Attorney (incorporated by reference to the signature page of
this Annual Report on Form 10-K).
|
|
|
Certification
Statement of Chief Executive Officer pursuant to Section 302(a) of
the Sarbanes-Oxley Act of 2002 (filed herewith).
|
|
| 31.2 |
|
Certification Statement of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 (filed herewith). |
|
32.1
|
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of
the Sarbanes-Oxley Act of 2002 (furnished
herewith).
|
|
101.INS
|
|
XBRL
Instance Document
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document
|
|
|
AEHR TEST
SYSTEMS
|
|
|
|
|
|
|
|
|
Date
|
By:
|
/s/
GAYN
ERICKSON
|
|
|
|
|
Gayn Erickson
|
|
|
|
|
PRESIDENT AND CHIEF EXECUTIVE OFFICER |
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
President, Chief
Executive
|
|
|
|
|
|
Officer, and
Director
|
|
|
|
/s/
GAYN ERICKSON
|
|
(Principal
Executive Officer)
|
|
August
29, 2017
|
|
Gayn Erickson
|
|
Vice
President of Finance
|
|
|
|
|
|
and
Chief Financial Officer
|
|
|
|
/s/ KENNETH
B. SPINK
|
|
(Principal
Financial and
|
|
August
29, 2017
|
|
Kenneth B. Spink
|
|
|
|
|
|
|
|
|
|
|
|
/s/ RHEA J.
POSEDEL
|
|
Chairman
|
|
August
29, 2017
|
|
Rhea J. Posedel
|
|
|
|
|
|
|
|
|
|
|
|
/s/ ROBERT
R. ANDERSON
|
|
Director
|
|
August
29, 2017
|
|
Robert R. Anderson
|
|
|
|
|
|
|
|
|
|
|
|
/s/ WILLIAM
W. R. ELDER
|
|
Director
|
|
August
29, 2017
|
|
William W. R. Elder
|
|
|
|
|
|
|
|
|
|
|
|
/s/ MARIO M.
ROSATI
|
|
Director
|
|
August
29, 2017
|
|
Mario M. Rosati
|
|
|
|
|
|
|
|
|
|
|
|
/s/ JOHN M.
SCHNEIDER
|
|
Director
|
|
August
29, 2017
|
|
John M. Schneider
|
|
|
|
|
|
|
|
|
|
|
|
/s/ HOWARD
T. SLAYEN
|
|
Director
|
|
August
29, 2017
|
|
Howard T. Slayen
|
|
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|